Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyung-Bo Kim

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Cancer Drug Resistance (Alhambra, Calif.)|July 26, 2021
Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?Kyung Bo Kim
Current Topics in Medicinal Chemistry|August 10, 2011
The immunoproteasome: an emerging therapeutic targetWooin Lee, Kyung Bo Kim
Natural Product Reports|April 12, 2013
From epoxomicin to carfilzomib: chemistry, biology, and medical outcomesKyung Bo Kim, Craig M Crews
Cell Biochemistry and Biophysics|May 24, 2013
Activity-based imaging probes of the proteasomeKimberly Cornish Carmony, Kyung Bo Kim
Journal of Medicinal Chemistry|April 9, 2008
Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitorsKyung Bo Kim, Craig M Crews
Methods in Molecular Biology (Clifton, N.J.)|February 22, 2012
PROTAC-induced proteolytic targetingKimberly Cornish Carmony, Kyung-Bo Kim
Current Cancer Drug Targets|July 26, 2014
The immunoproteasome as a therapeutic target for hematological malignanciesZachary Miller, Wooin Lee, Kyung Bo Kim
Chembiochem : a European Journal of Chemical Biology|September 9, 2016
High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor DesignKimberly Carmony, Wooin Lee, Kyung Bo Kim
Current Protocols in Chemical Biology|July 10, 2013
Targeted Degradation of Proteins by PROTACsEun Ryoung Jang, Wooin Lee, Kyung Bo Kim
Molecular Biosystems|March 21, 2008
Proteasome modulators: essential chemical genetic tools for understanding human diseasesMarie Wehenkel, Jin Tae Hong, Kyung Bo Kim
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Cancer Drug Resistance (Alhambra, Calif.)|July 26, 2021
Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?Kyung Bo Kim
Current Topics in Medicinal Chemistry|August 10, 2011
The immunoproteasome: an emerging therapeutic targetWooin Lee, Kyung Bo Kim
Natural Product Reports|April 12, 2013
From epoxomicin to carfilzomib: chemistry, biology, and medical outcomesKyung Bo Kim, Craig M Crews
Cell Biochemistry and Biophysics|May 24, 2013
Activity-based imaging probes of the proteasomeKimberly Cornish Carmony, Kyung Bo Kim
Journal of Medicinal Chemistry|April 9, 2008
Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitorsKyung Bo Kim, Craig M Crews
Methods in Molecular Biology (Clifton, N.J.)|February 22, 2012
PROTAC-induced proteolytic targetingKimberly Cornish Carmony, Kyung-Bo Kim
Current Cancer Drug Targets|July 26, 2014
The immunoproteasome as a therapeutic target for hematological malignanciesZachary Miller, Wooin Lee, Kyung Bo Kim
Chembiochem : a European Journal of Chemical Biology|September 9, 2016
High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor DesignKimberly Carmony, Wooin Lee, Kyung Bo Kim
Current Protocols in Chemical Biology|July 10, 2013
Targeted Degradation of Proteins by PROTACsEun Ryoung Jang, Wooin Lee, Kyung Bo Kim
Molecular Biosystems|March 21, 2008
Proteasome modulators: essential chemical genetic tools for understanding human diseasesMarie Wehenkel, Jin Tae Hong, Kyung Bo Kim
Pageof 8